Please assess the completion status of the following clinical trial:

Trial Title: Organ-sparing With TraceIT® for Rectal Cancer Radiotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* WHO (World Health Organization) performance status 0-1 at registration~* Locally advanced (T1-2 node positive or T3 N0/N+) histologically proven rectal adenocarcinoma located in the middle or in the high rectum. Patients with tumors located in the lower rectum may be eligible if the location of the tumor do not preclude the implant of the spacer (i.e. tumors located anteriorly in the proximity of the anal sphincter)~* Indication for preoperative radiotherapy or radio-chemotherapy~* Absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial~* Before patient registration/randomization, written informed consent must be given according to GCP/ICH (Guideline for Good Clinical Practice/Harmonised Tripartite Guideline), and national/local regulations.~Exclusion Criteria:~* Patient \<18 years old~* WHO performance status ≥ 2 at registration~* Patient with a local extension, clinical stage T4 and/or presenting a vagina/prostate/bladder invasion~* Active bleeding disorder or clinically significant coagulopathy (PTT \>35sec/ or INR \>1.4 (INR, international normalized ratio). Or platelet count \< 100'000/mm3)~* Active inflammatory or infectious process involving the perineum, gastrointestinal or urinary tract~* Compromised immune system (e.g. HIV/acquired immunodeficiency syndrome, autoimmune disease or immunosuppressive therapy)~* History of previous pelvic surgery~* History of active inflammatory bowel disease (Crohn's disease, ulcerative colitis, irritable bowel disease)~* Contraindication for MRI~* Pregnant or lactating females~* Inability to provide a written informed consent~* Inability to comply with study and follow up procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).